Will Data Privacy Impact Health Research?

  • Lisbeth Ehlert Knudsen
  • Mette Due Theilade
  • Arnold Gordon
  • Jacques MascaroEmail author
  • Rudolf Bruppacher


European Community Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and the free movement of such data establishes a framework for the harmonization of regulations on the privacy of personal data. This directive has changed the regulatory framework in the European Union and has the potential to impact the use of human data generated during product development or postlicensing. This article reviews aspects and provisions of the directive and the ways in which it may affect clinical trial and data management activities. It evaluates existing safeguards and the ways in which they could minimize the negative effects of the directive without minimizing its noble and valid objective. The impact of regulations in other countries, specifically with regard to issues such as anonymization (defined by the American Society of Human Genetics as irreversibly stripping all identifiers from biological materials that were originally collected and identified and making them impossible to link to their sources) for privacy and use of data in relation to new technologies such as genetics and genomics are also covered.

Key Words

Data privacy Directive 95/46/EC European Community 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    European Community. Directive 95/46/EC of the European Parliament and the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Brussels, Belgium: European Community Commission; 1995.Google Scholar
  2. 2.
    Lowrance WW. The promise of human genetic databases. High ethical as well as scientific standards are needed. Br Med J. 2001;322(7293):1009–1010.CrossRefGoogle Scholar
  3. 3.
    Knudsen LE, Renneberg J. Regulatory aspects of the application of pharmacogenetics in drug discovery and development in Europe. Good Clin Pract. 2000; 7(6):11–13.Google Scholar
  4. 4.
    Theilade MD, Ehlert Knudsen L, Renneberg J. Regulatory requirements for inclusion of pharmacogenetic testing in applications for clinical trials in Europe. Regulatory Aff J. 2001; 12(2):92–99.Google Scholar

Copyright information

© Drug Information Association, Inc 2002

Authors and Affiliations

  • Lisbeth Ehlert Knudsen
    • 1
  • Mette Due Theilade
    • 2
  • Arnold Gordon
    • 3
  • Jacques Mascaro
    • 4
    Email author
  • Rudolf Bruppacher
    • 5
  1. 1.Institute of Public HealthUniversity of CopenhagenDenmark
  2. 2.Danish Medicines AgencyCopenhagenDenmark
  3. 3.GreenwichUSA
  4. 4.Johnson & Johnson, Pharmaceutical Research and DevelopmentHaw Lane SaundertonBucksUK
  5. 5.School of PharmacyUniversity of BaselBaselSwitzerland

Personalised recommendations